Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cytotherapy|January 23, 2024
Academic challenges on advanced therapy medicinal products' development: a regulatory perspectiveEulalia Olesti, Yoana Nuevo, Mireia Bachiller, et al.
Sensors (Basel, Switzerland)|April 28, 2018
Economic Analysis of the Reduction of Blood Transfusions during Surgical Procedures While Continuous Hemoglobin Monitoring Is UsedBorja Ribed-Sánchez, Cristina González-Gaya, Sara Varea-Díaz, et al.
Gaceta Sanitaria|February 21, 2018
Analysis of economic and social costs of adverse events associated with blood transfusions in SpainBorja Ribed-Sánchez, Cristina González-Gaya, Sara Varea-Díaz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2016
Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patientsMiguel Caballero-Baños, Daniel Benitez-Ribas, Jaime Tabera, et al.
Plos One|February 14, 2012
TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemiaCristina Pérez, Nicolas Martínez-Calle, José Ignacio Martín-Subero, et al.
Journal of the American College of Cardiology|September 7, 2014
A polypill strategy to improve adherence: results from the FOCUS projectJosé M Castellano, Ginés Sanz, José L Peñalvo, et al.
Frontiers in Immunology|November 3, 2025
Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002hDaniel Munárriz, Luis Gerardo Rodríguez-Lobato, Lucía López-Corral, et al.
British Journal of Haematology|June 4, 2026
Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvementCarlos Jimenez-Mira, Natalia Tovar, Núria Martínez-Cibrián, et al.
Blood Advances|November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myelomaInés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.
British Journal of Haematology|October 31, 2023
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
Pageof 2